



Attorney Docket No.: 6303.000-US (previously 452345/0007JJD/DLS)

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Aspe et al.

Application No.: 09/877,492

Group Art Unit: 3713

Filed: June 8, 2001

Examiner: Kathleen M. Christman

For: Adaptive Interactive Preceptored Teaching System

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent No. 5,867,821
2. U.S. Patent No. 5,924,074
3. U.S. Patent No. 5,940,802
4. U.S. Patent No. 5,954,641


5. U.S. Patent No. 6,014,631
6. U.S. Patent No. 6,018,713
7. U.S. Patent No. 6,024,699
8. U.S. Patent No. 6,076,166
9. U.S. Patent No. 6,085,752
10. U.S. Patent No. 6,102,855
11. U.S. Patent No. 6,139,495
12. U.S. Patent No. 6,151,581
13. U.S. Patent No. 6,161,095
14. U.S. Patent No. 6,168,563 B1
15. Memo from Dr. Geoffrey S. Gates of Mayo Clinic to Len Smith of Novo Nordisk® Pharmaceuticals, Inc. received February 9, 2004
16. Information concerning the American Diabetes Association 60<sup>th</sup> Scientific Sessions, San Antonio, June 9-13, 2000 and other materials provided by Stroock, Stroock and Lavan
17. Statement Concerning NovoTrack®/MayoTrack Presentations, Diabetes Monitors and Diabetes Management Web Sites
18. John D. Piette, BioMed Central, Abstract, Enhancing Support via Interactive Technologies
19. Nebel et al., Patient Education and Counseling, Vol. 46, Issue 1, pages 55-59 (2002)
20. Nebel et al., Abstract, University of Leipzig, Germany
21. Press Release, Area Malls Kick-Off Vismed Interactive Health Kiosks, [www.touchvision.com/pr/marion.htm](http://www.touchvision.com/pr/marion.htm) (2002)
22. Press Release, Novo Nordisk® Launches Interactive Diabetes Management Website [www.findarticles.com](http://www.findarticles.com) (2001)
23. Diabetes In Control.com, Issue 117, item 2 (2002)
24. Gates et al., International Diabetes Monitor, Vol. 15, No. 3, pages 1-6 (2003)
25. Smith et al., Diabetes Care, Vol. 21, No. 6, pages 972-976 (1998)
26. Montori et al., Diabetes Care, Vol. 25, No. 11, pages 1952-1957 (2002)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: February 17, 2004

Respectfully submitted,



Len S. Smith, Reg. No. 43,139

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, NJ 08540

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE

FORM PTO-1449  
Rev. 2-3-97U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAtty. Docket No. 6303.000-US  
(previously  
452345/0007JJD/DLS)

Serial No. 09/877,492

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Aspe et al.

Filing Date June 8, 2001

Group 3713

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,867,821	2/2/99	Ballantyne et al.	705	2	
	5,924,074	7/13/99	Evans	705	3	
	5,940,802	8/17/99	Hildebrand et al.	705	3	
	5,954,641	9/21/99	Kehr et al.	600	3	
	6,014,631	1/11/00	Teagarden et al.	705	3	
	6,018,713	1/25/00	Coli et al.	705	2	
	6,024,699	2/15/00	Surwit et al.	600	300	
	6,076,166	6/13/00	Moshfeghi et al.	713	201	
	6,085,752	7/11/00	Kehr et al.	128	897	

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Memo from Dr. Geoffrey S. Gates of Mayo Clinic to Len Smith of Novo Nordisk®
		Pharmaceuticals, Inc. received February 9, 2004
		Information concerning the American Diabetes Association 60 <sup>th</sup> Scientific Sessions, San Antonio, June 9-13, 2000 and other materials provided by Stroock, Stroock and Lavan
		Statement Concerning NovoTrack®/MayoTrack Presentations, Diabetes Monitors and Diabetes Management Web Sites
		John D. Piette, BioMed Central, Abstract, Enhancing Support via Interactive Technologies
		Nebel et al., Patient Education and Counseling, Vol. 46, Issue 1, pages 55-59 (2002)
		Nebel et al., Abstract, University of Leipzig, Germany

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6303.000-US  
(previously  
452345/0007JJD/DLS)

Serial No. 09/877,492

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Aspe et al.**

Filing Date **June 8, 2001**

Group **3713**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,102,855	8/15/00	Kehr et al.	600	300	
	6,139,495	10/31/00	De La Huergera	600	300	
	6,151,581	11/21/00	Kraftson et al.	705	3	
	6,161,095	12/12/00	Brown	705	2	
	6,168,563 B1	1/2/01	Brown	600	301	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Press Release, Area Malls Kick-Off Vismed Interactive Health Kiosks, www.touchvision.com/pr/marion.htm (2002)
		Press Release, Novo Nordisk® Launches Interactive Diabetes Management Website www.findarticles.com (2001)
		Diabetes In Control.com, Issue 117, item 2 (2002)
		Gates et al., International Diabetes Monitor, Vol. 15, No. 3, pages 1-6 (2003)
		Smith et al., Diabetes Care, Vol. 21, No. 6, pages 972-976 (1998)
		Montori et al., Diabetes Care, Vol. 25, No. 11, pages 1952-1957 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.